Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Arcadia Biosciences (RKDA) Gets a Buy from Lake Street

Tipranks - Tipranks - Fri Mar 21, 2025

In a report released today, Ben Klieve from Lake Street maintained a Buy rating on Arcadia Biosciences (RKDA – Research Report), with a price target of $12.00. The company’s shares closed yesterday at $3.30.

Light Up your Portfolio with Spark:

According to TipRanks, Klieve is a 3-star analyst with an average return of 2.6% and a 39.83% success rate. Klieve covers the Consumer Defensive sector, focusing on stocks such as Vital Farms, Lifeway Foods, and Calavo Growers.

Arcadia Biosciences has an analyst consensus of Hold.

See Insiders’ Hot Stocks on TipRanks >>

Based on Arcadia Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.54 million and a GAAP net loss of $1.61 million. In comparison, last year the company earned a revenue of $1.6 million and had a GAAP net loss of $2.57 million

Read More on RKDA:

Questions or Comments about the article? Write to editor@tipranks.com
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).